2024 annual financial data
Avalo Therapeutics 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -11,123.81%.
Operating income was -68,512,000 USD and net income was -35,129,000 USD.
Operating cash flow was -49,056,000 USD.
Get free Avalo Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 441,000 USD
- Operating income
- -68,512,000 USD
- Net income
- -35,129,000 USD
- Operating cash flow
- -49,056,000 USD